Advances in lenvatinib monotherapy and combination therapies in anaplastic thyroid cancer (Review)
Oncology Letters · 11.06.2025 · 30 (2) · 1-13
DOI: 10.3892/ol.2025.15139 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Letters, online erschienen am 11.06.2025. Verfasst von Lisha Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medicine Department, School of Medicine, Ningbo University, Ningbo, Zhejiang 315000, P.R. China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Anaplastic thyroid cancer (ATC) is a highly malignant and aggressive endocrine tumor with the poorest prognosis among all thyroid cancer (TC) subtypes. Although ATC is extremely rare, treatment remains a notable challenge, as traditional therapies have exhibited very limited efficacy. Targeted small-molecule inhibitors that disrupt molecular signaling pathways offer a potential therapeutic approach for patients with ATC. Lenvatinib, a tyrosine kinase inhibitor, has emerged as a promising therapeutic agent, which targets various factors involved in angiogenesis and tumor progression, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor α, fibroblast growth factor receptor and mast/stem cell growth factor receptor. Preclinical and clinical trials have demonstrated the efficacy of lenvatinib, both as monotherapy and in combination with other targeted therapy, chemotherapy, immunotherapy, warranting a comprehensive review of these studies. However, lenvatinib monotherapy was associated with a high incidence of adverse events (including hypertension, anorexia and proteinuria) and certain limitations, particularly drug resistance, emphasizing the need for optimized therapeutic strategies. In the present review, the efficacy and safety of lenvatinib monotherapy and combination therapies in the treatment of ATC were examined. Furthermore, the feasibility and limitations of different combination therapies were analyzed and compared. The present review aimed to provide insights into potential lenvatinib-based regimens that could enhance survival outcomes and improve the quality of life for patients with ATC in the future.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Medicine Department, School of Medicine, Ningbo University, Ningbo, Zhejiang 315000, P.R. China.
- Department of Thyroid Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315000, P.R. China.
Zitieren
APA
Xu, L., Zhang, W., Wang, Y., Le, Q., Xie, Y., Yu, K., & Wu, X. (2025). Advances in lenvatinib monotherapy and combination therapies in anaplastic thyroid cancer (Review). Oncology Letters, 30(2), 1-13. https://doi.org/10.3892/ol.2025.15139
Vancouver
Xu L, Zhang W, Wang Y, Le Q, Xie Y, Yu K, et al. Advances in lenvatinib monotherapy and combination therapies in anaplastic thyroid cancer (Review). Oncology Letters. 2025;30(2):1-13. doi:10.3892/ol.2025.15139
BibTeX
@article{Xu2025,
author = {Xu, Lisha and Zhang, Weidong and Wang, Yinchun and Le, Qi and Xie, Yue and Yu, Kejie and Wu, Xianjiang},
title = {Advances in lenvatinib monotherapy and combination therapies in anaplastic thyroid cancer (Review)},
journal = {Oncology Letters},
year = {2025},
volume = {30},
number = {2},
pages = {1--13},
doi = {10.3892/ol.2025.15139}
}
EUVIMED